

Risankizumab

Cat. No.:	HY-P99248
CAS No.:	1612838-76-2
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit ($K_d < 10$ pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes ($IC_{50} = 2$ pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis ^{[1][2][3]} .		
IC ₅₀ & Target	IL-23 <10 pM (K_d)		
In Vitro	<p>Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with K_ds <10 pM^[3].</p> <p>Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC_{50}s of 2 pM and 17 pM, respectively^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>		
In Vivo	Risankizumab (BI 655066) (1 mg/kg; i.p.; single dosage) inhibits IL23-induced mice ear swelling and cytokine production ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Mice (injected with BI 655066, 1 h later injected recombinant human IL23 into the skin of the mouse ear for 4 days) ^[3]	
	Dosage:	1 mg/kg	
	Administration:	i.p.; single dosage	
	Result:	Significantly inhibited IL23-induced ear swelling and cytokine production.	
	Animal Model:	Cynomolgus monkeys ^[3]	
	Dosage:	1.0 mg/kg	
	Administration:	i.v. or s.c.	
	Result:	Pharmacokinetic Parameters of Risankizumab (BI 655066) in cynomolgus monkeys ^[1] .	

	IV (1 mg/kg)	SC (1 mg/kg)
AUC _{inf} (μg·day/mL)	202 ± 33.5	142 ± 33.3
CL (mL/day/kg)	5.18 ± 0.8	/
Vd, ss (mL/kg)	88.3 ± 3.12	/
t _{1/2} (h)	12.2 ± 2.28/	9.15 ± 1.87
C _{max} (μg/mL)	/	10.1 ± 3.14
T _{max} (day)	/	2.11 ± 1.84
F (%)	/	70.4 ± 16.5

REFERENCES

- [1]. McKeage K, Duggan S. Risankizumab: First Global Approval. *Drugs*. 2019 Jun;79(8):893-900.
- [2]. Andrea Chiricozzi, et al. Risankizumab for the treatment of moderate to severe psoriasis. *Expert Opinion on Biological Therapy*. Volume 19, 2019 - Issue 1
- [3]. Singh S, et al. Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. *MAbs*. 2015;7(4):778-91.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA